ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates

On November 9, 2026 ADC Therapeutics SA (NYSE: ADCT) reported full financial results for the third quarter ended September 30, 2026, and provided recent operational updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics’ balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "In addition, we continue to deliver on sales while focusing on opportunities to expand ZYNLONTA’s role in the treatment of B-cell malignancies to drive growth. With multiple abstracts accepted for presentation at ASH (Free ASH Whitepaper), including the full results from LOTIS-7, we look forward to highlighting the breadth of ZYNLONTA’s clinical potential at this meeting."

"As treatment options for patients with B-cell malignancies continue to evolve, we believe ZYNLONTA has an opportunity to play an important role in addressing significant unmet needs," said Mohamed Zaki, M.D., Ph.D., Chief Medical Officer of ADC Therapeutics. "The upcoming LOTIS-7 Phase 1b and marginal zone lymphoma IIT data at ASH (Free ASH Whitepaper) highlights the potential for ZYNLONTA to play an important role in the treatment of r/r DLBCL and indolent lymphomas. We plan to use these findings to guide our clinical development priorities and regulatory strategy."

Third Quarter 2026 Operational Updates and Recent Milestones

Strategic financial restructuring strengthens balance sheet and supports continued investment in ZYNLONTA. In October 2026, the Company announced a comprehensive strategic financial restructuring that included an $86.6 million private investment in public equity (PIPE) financing with participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. As part of the PIPE, approximately 12.9 million common shares were issued, as well as 48 million warrants with a strike price of CHF 0.08. The Company also amended its HealthCare Royalty financing agreement to eliminate a $150 million change-of-control payment, amended its senior secured loan agreement to reduce outstanding principal by $68.5 million to $50 million, eliminated scheduled principal amortization and removed the minimum liquidity covenant.

These transactions strengthened the Company’s capital structure, enhanced strategic optionality and extended the expected cash runway into 2029.

Multiple ZYNLONTA abstracts, including five oral presentations, to be presented at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. Multiple abstracts highlighting ZYNLONTA’s potential across multiple B-cell malignancies have been accepted for presentation at ASH (Free ASH Whitepaper) in December. Oral presentations will feature updated results from the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with glofitamab in relapsed or refractory large B-cell lymphoma; full results from the Phase 3 LOTIS-5 trial evaluating ZYNLONTA in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL); and investigator-initiated studies (IITs) in marginal zone lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia.

Continued progress toward potential commercialization of ZYNLONTA in Japan. ADC Therapeutics’ Japanese licensing partner, Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation), has submitted a marketing authorization application with Japan’s Ministry of Health, Labor and Welfare for ZYNLONTA to treat patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. Tanabe Pharma has also entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd., for the commercialization of ZYNLONTA in Japan.

Third Quarter 2026 Financial Results

Product Revenues: Net product revenues were $21.0 million and $59.7 million for the third quarter and nine months ended September 30, 2026, as compared to $15.8 million and $51.2 million for the same periods in 2025. The increase period-over-period was primarily driven by volume increase.

License Revenues and Royalties: License revenue and royalties were $0.7 million and $2.1 million for the third quarter and nine months ended September 30, 2026, as compared to $0.7 million and $7.1 million for the same periods in 2025. The decrease for the nine-month period was primarily driven by a prior-year milestone received from our partner.

Cost of Product Sales: Cost of product sales was $2.0 million and $7.9 million for the third quarter and nine months ended September 30, 2026, as compared to $1.2 million and $4.1 million for the same periods in 2025. The increase in cost of product sales was primarily attributable to a change in focus of certain personnel costs from research and development clinical supply activities to commercial manufacturing activities.

Research and Development (R&D) Expense: R&D expense was $14.7 million and $52.0 million for the third quarter and nine months ended September 30, 2026, as compared to $26.8 million and $85.8 million for the same periods in 2025. The decrease in R&D costs was primarily driven by a reduction in spending on discontinued programs, completion of the IND-enabling activities for our PSMA-targeting ADC and lower ZYNLONTA spend. The decrease was also driven by a shift of certain personnel costs reflecting a change in focus from research and development activities toward commercial manufacturing and fulfillment activities. A total of $1.7 million for the quarter and $5.5 million for the nine-month periodwas allocated to cost of product sales ($1.0 million QoQ/$3.3 million YoY), inventory capitalization and selling and marketing expense.

Selling and Marketing (S&M) Expense: S&M expense was $8.7 million and $34.0 million for the third quarter and nine months ended September 30, 2026, as compared to $10.7 million and $31.4 million for the same periods in 2025. The decrease quarter-over-quarter was primarily due to lower marketing and advertising expenses. The increase for the nine-month period was primarily driven by higher cash-based retention and incentive awards.

General & Administrative (G&A) Expense: G&A expense was $10.7 million and $30.3 million for the third quarter and nine months ended September 30, 2026, as compared to $8.3 million and $27.1 million for the same periods in 2025. The increase period-over-period was primarily due to increased professional expenses, cash-based retention awards and share-based compensation expense, partially offset by lower wages and benefits.

Restructuring, impairment and other related costs: In connection with the strategic reorganization and workforce reduction announced in June 2026, we recognized $0.1 million in expense reversal for the third quarter and $2.6 million in employee severance and related benefit costs for the nine months ended September 30, 2026. In connection with the strategic reprioritization and restructuring plan announced in June 2025, we incurred $0.4 million and $13.5 million in restructuring, impairment and other related costs for the third quarter and nine months ended September 30, 2025, which consisted of $6.2 million in employee severance and related benefit costs, $6.4 million in non-cash impairment of assets and $0.8 million in retirement costs in connection with the close down of the UK facility.

Total Operating Expenses and Adjusted Total Operating Expenses: Total operating expenses were $36.1 million and $126.8 million for the third quarter and nine months ended September 30, 2026, as compared to $47.4 million and $161.9 million for the same periods in 2025, a reduction of 24% and 22%, respectively. On a non-GAAP basis, total adjusted operating expenses were $32.1 million and $112.1 million for the third quarter and nine months ended September 30, 2026, as compared to $45.0 million and $141.9 million for the same periods in 2025, a reduction of 29% and 21%, respectively. The reduction in total adjusted operating expenses was primarily driven by lower R&D expenses.

Net Loss and Adjusted Net Loss: Net loss for the third quarter and nine months ended September 30, 2026, was $25.3 million or $74.8 million, or a net loss of $0.16 and $0.48 per basic and diluted share, as compared to a net loss of $41.0 million and $136.2 million, or a net loss of $0.30 and $1.14 per basic and diluted share, for the same periods in 2025. On a non-GAAP basis, adjusted net loss for the third quarter and nine months ended September 30, 2026, was $8.8 million and $44.8 million, or a net loss of $0.06 and $0.29 per basic and diluted share, as compared to a net loss of $25.5 million and $78.2 million, or a net loss of $0.19 and $0.66 per basic and diluted share, for the same periods in 2025. The lower net loss and adjusted net loss were primarily due to lower operating expenses and, on a per basic and diluted share basis, by a higher number of weighted average shares outstanding. Net loss was also favorably impacted by the change in fair value of warrants and the cumulative catch-up adjustment of the Company’s deferred royalty obligation.

Cash and Cash Equivalents: As of September 30, 2026, cash and cash equivalents were $189.2 million, compared to $261.3 million as of December 31, 2025, a change primarily driven by cash used in operations. The Company has an expected cash runway into 2029.

(Press release, ADC Therapeutics, NOV 9, 2026, View Source [SID1234674460])

Immunocore to present at upcoming investor conferences

On November 9, 2026 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported management will participate at the following conferences in November.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UBS Global Biopharma Conference 2026
Fireside Chat: Tuesday, November 17, 2026, at 3:20 p.m. GMT

Jefferies London Global Healthcare Conference
1×1 and small group meetings: Wednesday, November 18, 2026

The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

(Press release, Immunocore, NOV 9, 2026, View Source [SID1234674476])

Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 9, 2026 Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, reported financial results for the quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We made significant progress across our oncology pipeline in recent months," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. "We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA. Beyond varegacestat, we now have three programs in the clinic, with IM-1340 expected to become the fourth by year-end. We are progressing the Phase 1 study of IM-1021, our ROR1-targeted ADC, and look forward to presenting updated Phase 1 data at ASH (Free ASH Whitepaper) in December."

Pipeline Highlights

Varegacestat:

•
The U.S. FDA accepted the varegacestat NDA in July 2026 and assigned a PDUFA target action date of April 28, 2027.
•
In October 2026, the EMA validated Immunome’s MAA for varegacestat for the treatment of adults with desmoid tumors.
•
Additional Phase 3 RINGSIDE data, including patient-reported outcomes, were presented across three posters and a rapid oral session at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress.

IM-1021: The Phase 1 clinical trial of IM-1021 is ongoing, and Immunome expects to present an updated dataset at the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting on December 14, 2026. Previously reported results as of the June 26, 2026 abstract data cutoff included:

•
Among 11 response-evaluable patients with diffuse large B-cell lymphoma (DLBCL), the objective response rate was 64% (7/11), including three complete responses. Across all 19 response-evaluable patients with B-cell non-Hodgkin lymphoma (B-NHL), the objective response rate was 53% (10/19), including five complete responses.
•
Among 25 treated B-NHL patients, treatment-emergent adverse events (TEAEs) were reported in 92%. Grade 3 or higher TEAEs occurred in 52% of B-NHL patients, of which the most common was neutropenia (44%).

IM-1617: In June 2026, the first patient was dosed in the Phase 1, first-in-human trial evaluating IM-1617 in patients with advanced solid tumors. IM-1617 is an ADC directed at an undisclosed solid tumor target and incorporates HC74, Immunome’s proprietary TOP1 inhibitor payload. The study is expected to include participants with advanced solid tumors, including colorectal cancer, non-small cell lung cancer and breast cancer.

IM-1340: Immunome received IND clearance for IM-1340 in September 2026. The company plans to initiate a Phase 1 trial by year-end. IM-1340 is a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporates HC74, Immunome’s proprietary TOP1 inhibitor payload. The trial is expected to include patients with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, small cell lung cancer and neuroendocrine neoplasms.

IM-3050: In July 2026, the first patient was dosed in the Phase 1, first-in-human trial evaluating IM-3050 in patients with FAP-expressing advanced solid tumors. The trial is designed to evaluate safety, tolerability, dosimetry, pharmacokinetics and preliminary anti-tumor activity of the investigational FAP-targeted radioligand therapy.

Preclinical ADC Pipeline: Immunome expects to submit an IND for IM-1335 in late 2026. The program is directed at an undisclosed solid tumor target and incorporates HC74. Additional undisclosed ADCs are in discovery and lead optimization to support INDs in 2027 and beyond.

Third Quarter 2026 Financial Results

•
As of September 30, 2026, cash, cash equivalents and marketable securities totaled $461.6 million. Immunome expects its current cash position to fund operations into 2028.
•
Research and development expenses for the quarter ended September 30, 2026, were $69.5 million, including stock-based compensation expense of $6.6 million.
•
General and administrative expenses for the quarter ended September 30, 2026, were $20.9 million, including stock-based compensation expense of $6.2 million.
•
Immunome reported a net loss of $85.8 million for the quarter ended September 30, 2026.

(Press release, Immunome, NOV 9, 2026, View Source [SID1234674496])

Inocras to Present New Results from Agentic AI Framework for Scaling Cancer Whole-Genome Sequencing Interpretation at AMP 2026

On November 9, 2026 Inocras Inc., a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, reported that it will present the first public results from its multimodal agentic AI framework for automating variant curation and clinical interpretation of cancer whole-genome sequencing (WGS) analysis at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo, taking place November 10–14 in Seattle.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Developed to address a key scalability bottleneck in clinical Cancer WGS analysis, the AI framework is a preview of Inocras’s CancerVision workflow innovation. In its latest evaluation, the framework achieved 99.5% agreement with expert curation among accepted calls, while deferring 10.2% of candidate variants for expert review. It also demonstrated 98.4% reproducibility across all candidate variants in repeated analyses with identical inputs and settings and is projected to reduce expert review time by more than half.

"Whole-genome sequencing offers a comprehensive view of cancer genomes, but interpreting the volume of data can be challenging," said Jehee Suh, CEO of Inocras. "Our AI framework aims to streamline this process, making WGS more practical for clinical use by reducing curation workload while maintaining expert oversight."

Unlike approaches based primarily on genomic annotations, Inocras’s new AI framework combines multiple types of evidence that expert curators traditionally assess. The agent can perform a structured review of candidate driver variants using genomic annotations and sequencing metrics and, when additional evidence is needed, can visually inspect sequencing read alignments and retrieve internal knowledge base, expert-curated historical cases.

Inocras is continuing to accumulate additional real-world performance evidence while continuously refining the agent through expert feedback. Human experts retain responsibility for the review and sign-off on all clinical reports.

"Variant curation is becoming an increasingly important rate-limiting step as WGS moves toward broader clinical adoption," said WonChul Lee, CIO and Head of the Innovation Lab at Inocras. "By combining multimodal reasoning, historical expert knowledge, and continuous feedback, our AI framework will be able to automate routine decisions while directing expert attention to the cases that require it most."

Inocras’s AMP presentation, "A Multimodal Agentic AI Framework for Scalable Variant Curation and Clinical Interpretation of Cancer Whole-Genome Sequencing," will be presented by Hansol Park of Inocras’s Data-Centric AI team.

Oral Presentation

Session: Platform Presentations of Selected Informatics Abstracts I
Date: Thursday, November 12, 2026
Time: 2:30–2:45 PM
Presentation: I024 — A Multimodal Agentic AI Framework for Scalable Variant Curation and Clinical Interpretation of Cancer Whole-Genome Sequencing
Location: Room 608–609, Level 6, Arch Building, Seattle Convention Center, 705 Pike St., Seattle, WA
Poster Presentation

Poster Number: I024
Abstract Number: 2465932
Category: Informatics
Poster Display Dates: November 12–14, 2026
Presentation Date: Friday, November 13, 2026
Presentation Time: 9:15–10:15 AM
Location: Expo Hall, Seattle Convention Center

(Press release, Inocras, NOV 9, 2026, View Source [SID1234674516])

Aldeyra Therapeutics provided an update on ADX-2191 for the treatment of primary vitreoretinal lymphoma

On November 9, 2026 Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") reported that the Company has formally requested that the Division of Ophthalmology (the "DO") of the U.S. Food and Drug Administration (the "FDA") submit a review jurisdiction request to the FDA’s Office of New Drugs (the "OND") recommending that review of the Company’s Investigational New Drug application (the "IND") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL") be transferred to the FDA’s Division of Hematologic Malignancies 2 ("DHM2"). Aldeyra made this request because lymphoma reviews are typically conducted by DHM2, which maintains expertise in local and systemic manifestations of hematogenous cancers. In connection with this request, Aldeyra notified the FDA that it had withdrawn the Special Protocol Assessment (the "SPA") protocol for ADX-2191 for the treatment of PVRL, which the DO had previously reviewed and agreed to. The submission of the review jurisdiction request is within the DO’s control, and any decision on the request is within the FDA’s discretion. While the jurisdictional request is pending, the Company does not expect to initiate the clinical trial contemplated by the SPA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following risk factor supplements, and should be read together with, the risk factors previously disclosed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026; June 30, 2026; and September 30, 2026.

We have requested that review of our Investigational New Drug application (the "IND") for ADX-2191 in primary vitreoretinal lymphoma be transferred to a different U.S. Food and Drug Administration (the "FDA") review division, and we have withdrawn our Special Protocol Assessment ("SPA") protocol for the planned clinical trial. As a result, the regulatory path for ADX-2191 in this indication is uncertain, may be significantly delayed, and may not lead to approval, and these actions could adversely affect our interactions with the FDA on our other programs, including reproxalap.

In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations. We subsequently reached agreement with the Division of Ophthalmology (the "DO") of the FDA under a SPA on the design and planned analysis of a clinical trial intended to support a resubmission of the NDA.

On November 9, 2026, we announced that we requested that the DO submit a review jurisdiction request to the FDA’s Office of New Drugs ("OND") recommending that review of the ADX-2191 IND be transferred to the Division of Hematologic Malignancies 2 ("DHM2"). In connection with this request, we notified the FDA that we had withdrawn the SPA protocol, and we will no longer have the benefit of the DO’s agreement on the design and planned analysis of the trial. The submission of the request is within the DO’s control, and the decision is within the FDA’s discretion. We cannot predict whether or when the DO will submit the request, what the DO will recommend, or whether or when the OND will make a decision. The OND may deny the request or transfer the IND to a division other than DHM2. If the IND remains with the DO, our withdrawal of the SPA and our transfer request could adversely affect the DO’s review of ADX-2191. If the IND is transferred, the new division will not be bound by any prior agreement or position of the DO, may disagree with the trial design or with positions the DO previously took, and may recommend different or additional trials, data, or analyses. The FDA has previously recommended trials for ADX-2191 for the treatment of proliferative vitreoretinopathy that we did not deem feasible, which led us to cease development in that indication, and we may reach a similar conclusion regarding the development of ADX-2191 for the treatment of PVRL.

While the jurisdictional request is pending, we do not expect to initiate the planned trial, and we expect that the clinical program for ADX-2191 for the treatment of PVRL will need to be redesigned. Any redesigned trial (or trials) may be larger, longer or more costly; may be more difficult to enroll given the rarity of PVRL; and could delay or prevent our ability to obtain the orphan drug exclusivity that may be available under the orphan drug designation we hold for ADX-2191 in PVRL, including if another methotrexate-based product obtains approval and orphan drug exclusivity for the same indication first.

Any of these outcomes could delay or prevent an NDA resubmission for, or approval of, ADX-2191 in PVRL; increase our costs; shorten our projected cash runway; require us to raise additional capital sooner than expected; and materially harm our business, financial condition, results of operations and stock price.

(Press release, Aldeyra Therapeutics, NOV 9, 2026, View Source [SID1234674461])